术中电子FLASH放疗设备临床原型机的临床前验证
本研究评估术中电子FLASH放疗临床原型机(CPIO-EFLASH)在源皮距50 cm下能否实现超高剂量率、控制肿瘤并触发FLASH组织保护效应。结果显示UHDR-RT实际剂量率为192–473 Gy/s,抑瘤效果与CONV-RT无显著差异,但全脑照射后空间学习记忆更优、全胸和全腹照射后生存率更高、肺肠皮肤损伤更轻。
要点
- CPIO-EFLASH在SSD 50 cm下可实现≥40 Gy/s的超高剂量率。
- UHDR-RT抑瘤效果与CONV-RT无显著差异。
- UHDR-RT在全脑、全胸、全腹及皮肤照射中显示正常组织保护效应。
核心结论
- CPIO-EFLASH可实现超高剂量率并触发显著正常组织保护效应,将电子FLASH技术整合入术中放疗可能带来临床获益。
研究设计与样本
- 使用皮下荷瘤小鼠(4T1乳腺癌、U87-MG胶质瘤、PAN02胰腺癌)和健康C57BL/6雌性小鼠进行临床前研究。
- 健康小鼠接受全脑、全胸、全腹和单腿照射,比较UHDR-RT(≥40 Gy/s)、CONV-RT(0.07 Gy/s)和假照射对照。
主要发现
- UHDR-RT实际剂量率为192–473 Gy/s。
- UHDR-RT与CONV-RT在肿瘤生长抑制上无显著差异。
- 全脑照射后2个月UHDR-RT空间学习记忆能力优于CONV-RT。
- 全胸照射后120天和全腹照射后90天UHDR-RT生存率显著更高,CONV-RT组肺和肠组织损伤更严重。
- 照射后2至8周UHDR-RT放射性皮肤损伤更轻。
关键数值与推荐
- UHDR-RT定义为≥40 Gy/s,CONV-RT为0.07 Gy/s。
- CPIO-EFLASH在SSD 50 cm下可达到≥40 Gy/s的超高剂量率。
临床怎么用
- 术中电子FLASH放疗可在有效治疗肿瘤的同时减轻正常组织损伤,支持进一步开展CPIO-EFLASH术中放疗临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This study aimed to evaluate whether the clinical prototype of intraoperative electron FLASH radiotherapy (CPIO-EFLASH), with a source-surface distance (SSD) of 50 cm, could achieve ultra-high dose rates, effectively control tumors, and trigger the FLASH tissue-sparing effect in preclinical models. MATERIALS AND METHODS: Subcutaneous tumor-bearing mice (4T1 breast cancer, U87-MG glioma, PAN02 pancreatic cancer) and healthy C57BL/6 female mice (whole-brain, thorax, abdomen and single-leg irradiation) were subjected with ultra-high dose rate radiotherapy (UHDR-RT, ≥ 40 Gy/s), conventional doserate radiotherapy (CONV-RT,0.07 Gy/s), or sham radiotherapy (Control). We evaluated survival status, tumor growth suppression, apoptosis, proliferation, and DNA damage in tumor tissues, along with radiation-induced injuries to the brain, lung, intestine, and skin tissues. RESULTS: The actual dose rates of UHDR-RT ranged from 192 to 473 Gy/s. No significant difference in tumor growth suppression was observed between the UHDR-RT and CONV-RT. Two months post whole-brain irradiation, UHDR-RT demonstrated better spatial learning and memory abilities compared to CONV-RT. At 120 days post whole-thorax irradiation and 90 days post whole-abdomen irradiation, the survival rates of UHDR-RT were also significantly higher. Histological analyses revealed more severe injury to lung and intestinal tissues in the CONV-RT group. Additionally, UHDR-RT exhibited milder radiation-induced skin injury from 2 to 8 weeks post-irradiation. CONCLUSION: The CPIO-EFLASH can achieve ultra-high dose rates (≥ 40 Gy/s at an SSD of 50 cm) and trigger significant normal tissue-sparing effects. Integrating electronic FLASH technology into intraoperative radiotherapy may bring potential clinical benefits by effectively treating tumors, while minimizing radiation-induced injury to normal tissues. Our findings highlight the necessity for further clinical trials of CPIO-EFLASH in intraoperative radiotherapy.
引用
- Hao X, Du H, Lin B, et al. Preclinical validation of a clinical prototype of intraoperative electron FLASH radiotherapy equipment: key evidence for a new radiotherapy paradigm. Radiat Oncol. 2025. PMID: 41437387. doi:10.1186/s13014-025-02781-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。